The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Teva- Pharmaceutical Industries Ltd. ADR shares valued at $91,748 were sold by Jover Placid on Aug 01 ’25. At $15.16 per share, Jover Placid sold 6,053 shares. The insider’s holdings dropped to 6,774 shares worth approximately $0.11 million following the completion of this transaction.
Also, Hughes Eric A sold 52,742 shares, netting a total of over 799,437 in proceeds. Following the sale of shares at $15.16 each, the insider now holds 0 shares.
Before that, Jover Placid had added 6,053 shares to its account. In a trade valued at $91,748, the Officer bought Teva- Pharmaceutical Industries Ltd. ADR shares for $15.16 each.
As published in their initiating research note from Goldman on June 06, 2025, Teva- Pharmaceutical Industries Ltd. ADR [TEVA] has been a Buy and the price target has been revised to $24. Analysts at Truist started covering the stock with ‘”a Buy”‘ outlook in a report released in late May. As of May 12, 2025, JP Morgan has increased its “Neutral” rating to a “an Overweight” for TEVA. Earlier on July 10, 2024, Argus upgraded its rating. Their new recommendation was “a Buy” for TEVA stock which previously was a “a Hold”.
Analyzing TEVA Stock Performance
On last trading session, Teva- Pharmaceutical Industries Ltd. ADR [NYSE: TEVA] rose 1.91% to $16.01. The stock’s lowest price that day was $15.75, but it reached a high of $16.11 in the same session. During the last five days, there has been a drop of approximately -4.87%. Over the course of the year, Teva- Pharmaceutical Industries Ltd. ADR shares have dropped approximately -5.77%.
Is Teva- Pharmaceutical Industries Ltd. ADR subject to short interest?
Stocks of Teva- Pharmaceutical Industries Ltd. ADR saw a sharp rise in short interest on 2025-07-15 jumping by 13.43 million shares to 53.42 million. Data from Yahoo Finance shows that the short interest on 2025-06-13 was 40.0 million shares. A jump of 25.13% in short interest reflects a negative sentiment towards the stock. Despite the fact that short shares comprise just 5.24 of the overall float, the days-to-cover ratio (short ratio) jumped to 5.24.
Which companies own the most shares of Teva- Pharmaceutical Industries Ltd. ADR (TEVA)?
In terms of Teva- Pharmaceutical Industries Ltd. ADR share price expectations, FactSet research, analysts set an average price target of 22 in the next 12 months, up nearly 40.04% from the previous closing price of $15.71. Analysts anticipate Teva- Pharmaceutical Industries Ltd. ADR stock to reach 28 by 2025, with the lowest price target being 10. In spite of this, 8 analysts ranked Teva- Pharmaceutical Industries Ltd. ADR stock as Buy at the end of 2025. On March 08, 2024, JP Morgan assigned a price target of “a Neutral” to the stock and upgraded coverage with a $14.
